TargetBeta
FGFR3
fibroblast growth factor receptor 3 · also CEK2, JTK4, CD333, ACH · CD molecules
9 programs in company-led studies act on FGFR3, from 8 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 761 running | FGFR1, FGFR2, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB | ChEMBL |
| masitinibrule | AB Science | phase 3 | 384 running | KIT, PDGFRA, PDGFRB | ChEMBL |
| futibatinibrule | Otsuka | phase 3 | 104 running | FGFR1, FGFR2, FGFR4 | ChEMBL |
| infigratinibrule | BridgeBio | phase 3 | 173 running | FGFR1, FGFR2, FGFR4 | ChEMBL |
| vepugratinibrule | Eli Lilly | phase 3 | 53 running | – | NCIt |
| pemigatinibrule | Incyte | phase 3 | 161 running | FGFR1, FGFR2 | ChEMBL |
| dabogratinibrule | Tyra Biosciences | phase 2 | 55 running | – | NCIt |
| Anti-FGFR3 Antibody-drug Conjugate BHV-1530rule | Biohaven Therapeutics | phase 1 | 11 running | – | NCIt |
| FGFR3/4 Inhibitor TYRA-430rule | Tyra Biosciences | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Transitional Cell, 3 programs
- Cholangiocarcinoma, 3 programs
- Achondroplasia, 2 programs
- Urinary Bladder Neoplasms, 2 programs
- Adenocarcinoma Of Esophagus, 1 program
- Alzheimer Disease, 1 program
- Amyotrophic Lateral Sclerosis, 1 program
- Arthritis, Rheumatoid, 1 program
- Asthma, 1 program
- Biliary Tract Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026dabogratinib · Tyra Biosciences · phase 2 · NCT05544552
- Dec 2026futibatinib · Otsuka · phase 3 · NCT05727176
- Jan 2027infigratinib · BridgeBio · phase 3 · NCT06873035
- Jun 2027vepugratinib · Eli Lilly · phase 3 · NCT05614739
- Dec 2027masitinib · AB Science · phase 3 · NCT03127267
- Jan 2028FGFR3/4 Inhibitor TYRA-430 · Tyra Biosciences · phase 1 · NCT06915753
- Nov 14, 2028nintedanib · Boehringer Ingelheim · phase 4 · NCT07335562
- Mar 2029Anti-FGFR3 Antibody-drug Conjugate BHV-1530 · Biohaven Therapeutics · phase 1 · NCT06874335
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.